Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012-2017 Medicare Data

Ruben Niesvizky, MD, Zoe Clancy, Ronda Copher, PhD, Ryan B. Thomas, MD, Cynthia Z. Qi, MBA, Zheng-Yi Zhou, Miriam L. Zichlin, Sarah H. Koenigsberg, James E. Signorovitch

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-136284

Published: 2020

Journal Articles

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Danny Luan, MPH, Paul J Christos, Dr.P.H., M.S., Michael Ancharski, MLS(ASCP), Danielle Guarneri, BS, CCRP, Roger Pearse, MD PhD, Adriana C Rossi, MD MSc, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Adrienne A. Phillips, MD MPH, Jingmei Hsu, MD, Ljiljana V. Vasovic, MD, Yen-Michael S. Hsu, MD PhD, Koen van Besien, MD PhD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140811

Published: 2020

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Cara A. Rosenbaum, MD, Danny Luan, BS, MPH, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Koen Van Besien, MD PhD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 2026.

https://doi.org/10.1182/blood-2019-127710

Published: 2019

Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 4876.

https://doi.org/10.1182/blood-2019-122134

Published: 2019

Journal Articles

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Amrita Y. Krishnan, MD, Krina K. Patel, MD MSc, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Rebecca W. Silbermann, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Eric Robert Fedyk, BSc, MSc, PhD, Antonio Palumbo, MD, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 140.

https://doi.org/10.1182/blood-2019-128007

Published: 2019

Journal Articles

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Eloisi Caldas Lopes, PhD, Tai Wang, PhD, David S Jayabalan, MSc, Tony Taldone, PhD, Jorge Monge, MD, Jorge Contreras, MD, Yip Winnie, Vicenta Trujillo, PhD, Panchal Palak, Nicholas Lombardi, Sharma Sahil, PhD, Digwal Chander, PhD, Morton Coleman, MD, Gabriela Chiosis, PhD, Ruben Niesvizky, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 4399.

https://doi.org/10.1182/blood-2019-125267

Published: 2019

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Autologous Stem Cell Transplantation Outcomes in Patients with Myeloma and Renal Dysfunction

Jorge Monge, MD, David S Jayabalan, MSc, Ruben Niesvizky, MD, Morton Coleman, MD, Kari Flicker, BS, Robin S. Solomon, Adriana C. Rossi, MDMSc, Jin Guo, MD

Blood (2019) 134 (Supplement_1): 5573.

https://doi.org/10.1182/blood-2019-131919

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Jorge Monge, MD, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Jin Guo, MD, Jorge Contreras, MD, Kathleen Pogonowski, RN, Natalie Agudo, RN, Danielle Guarneri, BS, CCRP, Brielle Liotta, BS, Eloisi Caldas Lopes, PhD, Roger Pearse, MD PhD, Morton Coleman, MD, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2019) 134 (Supplement_1): 5563.

https://doi.org/10.1182/blood-2019-127697

Published: 2019

Journal Articles

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study

Philippe Moreau, David S Siegel, MD PhD, Hartmut Goldschmidt, MD, Ruben Niesvizky, MD, Sara Bringhen, MD, Robert Z Orlowski, MD PhD, Julie Blaedel, Zhao Yang, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2018-99-112571

Published: 2018

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms

Spencer Krichevsky, BS, Erica B Bhavsar, BS, Richard R. Furman, MD, Ruben Niesvizky, MD, Ellen K. Ritchie, MD, Giorgio Inghirami, MD, Joseph Scandura, MD PhD

Blood (2018) 132 (Supplement 1): 4285.

https://doi.org/10.1182/blood-2018-99-120322

Published: 2018

Journal Articles

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Blood (2018) 132 (Supplement 1): 4452.

https://doi.org/10.1182/blood-2018-99-115971

Published: 2018

Journal Articles

Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients

Blood (2018) 132 (Supplement 1): 2004.

https://doi.org/10.1182/blood-2018-99-112750

Published: 2018

Journal Articles

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Meletios A Dimopoulos, MD, Ruben Niesvizky, MD, Philippe Moreau, David S Siegel, MD PhD, Roman Hajek, MD PhD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Mei Huang, Anita Zahlten-Kumeli, Katja Weisel, MD

Blood (2018) 132 (Supplement 1): 3277.

https://doi.org/10.1182/blood-2018-99-118448

Published: 2018

Journal Articles

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MDMSc, Daniel W. Sherbenou, MDPhD, Andrew Hammes, MS, Adriana C. Rossi, MDMSc, Ruben Niesvizky, MD, David S Jayabalan, MSc, Scott Ely, MDMPH

Blood (2017) 130 (Supplement 1): 3059.

https://doi.org/10.1182/blood.V130.Suppl_1.3059.3059

Published: 2017

Journal Articles

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Benjamin Diamond, MD, David S Jayabalan, MSc, Roger Pearse, MD PhD, Art Perry, Karen Pekle, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2017) 130 (Supplement 1): 3102.

https://doi.org/10.1182/blood.V130.Suppl_1.3102.3102

Published: 2017

NARROW

Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012-2017 Medicare Data

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Autologous Stem Cell Transplantation Outcomes in Patients with Myeloma and Renal Dysfunction

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only